Germany-based biotech company BioNTech (BNTX-US) said on Friday (8th) that it has signed a five-year contract with the German Ministry of Health to produce and supply mRNA vaccines during the country’s emergency.

Under the framework agreement, BioNTech will retain and maintain the manufacturing capacity to produce at least 80 million mRNA vaccine doses per year to address potential public health threats, the company said in a statement.

“There is growing evidence that the COVID-19 pandemic will continue to pose a public health challenge for years to come,” said Sean Marett, BioNTech’s chief operating officer and chief commercial officer.

BioNTech did not specify any financial details of the agreement. Its shares rose 1.2% after the open on Friday.